The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.

"As we turned over the cards, Teva/Sanofi's TL1A program came out with flying colors," he said. "Not only did we confirm that it's a real TL1A, but also: in spite of one of the highest placebo ...

Sanofi announces buy back of shares from L’OréalParis, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from ...